Inmunómica traslacional en neoplasias hematológicas
Tel Aviv University
Tel Aviv, IsraelPublicaciones en colaboración con investigadores/as de Tel Aviv University (11)
2024
-
Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia
Blood Advances, Vol. 8, Núm. 18, pp. 4950-4959
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood, Vol. 141, Núm. 3, pp. 219-230
-
Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry
Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823
2022
-
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
HemaSphere, Vol. 6, Núm. 8
2021
-
Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 1, pp. 46-54.e4
-
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
British Journal of Haematology, Vol. 192, Núm. 5, pp. 869-878
2020
-
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Blood Cancer Journal, Vol. 10, Núm. 11
2018
-
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Nature Medicine, Vol. 24, Núm. 12, pp. 1867-1876
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631